
Primordia Lab raises nearly RMB 300 million for virtual cell research
The AMW Read
The round adds a company-level funding update in virtual cells, while model performance and commercial impact remain unverified.
Primordia Lab raises nearly RMB 300 million for virtual cell research
Shanghai-based Primordia Lab has completed a Pre-A funding round of nearly RMB 300 million, led by Legend Capital. Participating investors included CMC Capital and a JD-affiliated fund, while existing investors also contributed. The company previously raised nearly RMB 100 million across angel and angel-plus rounds. It plans to use the new funding for data collection, an automated platform, model development and hiring.
The round adds capital to the emerging market for biological models that predict how cells respond to interventions. Primordia Lab aims to connect model predictions with laboratory tests and use the resulting data to update its models. This approach could help address gaps in rare cell states or intervention settings that repeated measurements of similar cells may miss. The report describes the company's objectives but provides no independent evidence that its model can reliably predict cell responses.
For investors and builders, the key question is whether each cycle produces useful evidence, rather than simply more measurements. Relevant tests would compare predictions with matched controls and laboratory results across different cell backgrounds and interventions. The report does not disclose customer adoption, commercial revenue or validation results, leaving the platform's practical performance and commercial prospects unverified.